Innova Captab growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025
+31.1%+15.0%
+30.5%+20.5%
+22.5%+16.5%
+11.6%+35.9%
+11.6%+20.1%
+16.3%+19.6%
+12.7%+15.5%
+80.5%−56.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INNOVACAP₹1,051.10

Innova Captab Limited

· Pharma & Health
₹ CrorePeersMOREPENLABIOLCPFDCSENORESSANOFIORCHPHARMAGUJTHEMRPGLIFEMcap ₹6,015 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+15.0+31.1—
EBITDA Growth—+20.5+30.5—
EBIT Growth—+16.5+22.5—
Net Income Growth—+35.9+11.6—
EPS Growth—+20.1+11.6—
Total Assets Growth—+19.6+16.3—
Total Equity Growth—+15.5+12.7—
Cash from Operations Growth—-56.4+80.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.